Cargando…
AXL is a potential therapeutic target in dedifferentiated and pleomorphic liposarcomas
BACKGROUND: AXL is a well-characterized, protumorigenic receptor tyrosine kinase that is highly expressed and activated in numerous human carcinomas and sarcomas, including aggressive subtypes of liposarcoma. However, the role of AXL in the pathogenesis of well-differentiated (WDLPS), dedifferentiat...
Autores principales: | May, Caitlin D., Garnett, Jeannine, Ma, XiaoYan, Landers, Sharon M., Ingram, Davis R., Demicco, Elizabeth G., Al Sannaa, Ghadah A., Vu, Tona, Han, Lixia, Zhang, Yi, Kivlin, Christine M., Bolshakov, Svetlana, Kalam, Azad Abul, Liu, Juehui, Zhou, Fuguo, Broccoli, Dominique, Wang, Wei-Lien, Lazar, Alexander J., Pollock, Raphael E., Lev, Dina, Torres, Keila E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4647521/ https://www.ncbi.nlm.nih.gov/pubmed/26573603 http://dx.doi.org/10.1186/s12885-015-1916-3 |
Ejemplares similares
-
The hepatocyte growth factor receptor as a potential therapeutic target for dedifferentiated liposarcoma
por: Bill, Kate Lynn J., et al.
Publicado: (2015) -
Co-targeting PI3K, mTOR, and IGF1R with small molecule inhibitors for treating undifferentiated pleomorphic sarcoma
por: May, Caitlin D., et al.
Publicado: (2017) -
AXL Inhibition Enhances MEK Inhibitor Sensitivity in Malignant Peripheral Nerve Sheath Tumors
por: Landers, Sharon M., et al.
Publicado: (2020) -
Phase II study of neoadjuvant checkpoint blockade in patients with surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma
por: Keung, Emily Z., et al.
Publicado: (2018) -
Retroperitoneal dedifferentiated liposarcoma with osteosarcomatous dedifferentiation
por: Nguyen, Vinh N., et al.
Publicado: (2015)